Impact of counterfeit drugs on the formulary decision-making process.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2004 AND VI 39
Results: 253
1
2
First-time generic approvals.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 571
- Publication type:
- Article
3
Selected literature.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 591
- Publication type:
- Article
4
Select cardiovascular agents.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 591
- Publication type:
- Article
5
Obesity initiative targets associated health risks, high medical costs.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 590
- Publication type:
- Article
6
New guidance for generic drugs clarifies protocol, increases speed to market.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 590
- Publication type:
- Article
7
Rofecoxib hearings point to failures in clinical testing design, decision-making transparency.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 589
- Publication type:
- Article
8
$139 million to advance information technology, records.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 588
- Publication type:
- Article
9
Government, industry provide pharmaceutical policy outlook for 2005 and beyond.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 588
- Publication type:
- Article
10
Oral capecitabine more efficacious than IV 5-FU/LV in treating colon cancer.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 529
- Publication type:
- Article
11
Treatment options for the management of chronic obstructive pulmonary disease.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 542
- By:
- Publication type:
- Article
12
Nebivolol.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 532
- By:
- Publication type:
- Article
13
Repaglinide improves blood glucose control in patients with type 2 diabetes.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 528
- Publication type:
- Article
14
Darbepoetin alfa dosed every 2 weeks similar to weekly epoetin alfa in boosting Hb.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 530
- Publication type:
- Article
15
Safety labeling updates &new warnings.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 586
- Publication type:
- Article
16
Valdecoxib meta-analysis finds increased cardiovascular risk.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 586
- Publication type:
- Article
17
Weekly nesiritide may have greatest benefit in highest-risk heart failure patients.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 585
- Publication type:
- Article
18
Worldwide study finds that fluoroquinolones are still affective against CAP.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 584
- Publication type:
- Article
19
Impact of counterfeit drugs on the formulary decision-making process.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 577
- By:
- Publication type:
- Article
20
A year of novel pharmacologic agents in review.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 572
- Publication type:
- Article
21
FDA actions in brief.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 571
- Publication type:
- Article
22
Pipeline preview.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 568
- Publication type:
- Article
23
New molecular entities.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 568
- Publication type:
- Article
24
Management of biologics in multiple sclerosis.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
25
Novel biologic agents for multiple sclerosis and their impact on managed care.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
26
Current immunomodulatory therapies for multiple sclerosis.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
27
Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care.
- Published in:
- Formulary, 2004, v. 39, p. 15
- By:
- Publication type:
- Article
28
Management of Biologies in Multiple Sclerosis.
- Published in:
- Formulary, 2004, v. 39, p. 10
- By:
- Publication type:
- Article
29
Current Immunomodulatory Therapies for Multiple Sclerosis.
- Published in:
- Formulary, 2004, v. 39, p. 4
- By:
- Publication type:
- Article
30
Letter from the Editorial Chair.
- Published in:
- 2004
- By:
- Publication type:
- Letter
31
Treatment options for the management of chronic obstructive pulmonary disease.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
32
Nebivolol: a beta antagonist with novel pharmacologic properties.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
33
Hypertension and stroke.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 560
- Publication type:
- Article
34
Selected literature.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 560
- Publication type:
- Article
35
Illinois, Wisconsin specify safeguards, provisions in state-sponsored WWW prescription drug pharmacy.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 559
- Publication type:
- Article
36
ASHP, AMCP recommend criteria for Medicare formulary design, formulary decision-maker responsibilities.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 559
- Publication type:
- Article
37
Report lists steps to improve product quality regulatory system.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 558
- Publication type:
- Article
38
Suit alleges FDA overstepped jurisdiction in regulating compounding pharmacies.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 558
- Publication type:
- Article
39
Drug and Formulary Trends.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 556
- Publication type:
- Article
40
Erlotinib prolongs survival of patients with NSCLC.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 529
- Publication type:
- Article
41
Extended-release methylphenidate demonstrates greater improvement over atomoxetine in ADHD.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 528
- Publication type:
- Article
42
news in brief.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 530
- Publication type:
- Article
43
Atorvastatin lowers cholesterol, heart attack risk in patients with type 2 diabetes.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 525
- Publication type:
- Article
44
Tiered formulary copayment strata may affect participant drug choice.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 525
- Publication type:
- Article
45
Safety labeling updates & new warnings.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 524
- Publication type:
- Article
46
Oral contraceptive use may reduce risk of cardiovascular events, cancer.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 524
- Publication type:
- Article
47
FDA directs antidepressant manufacturers to add pediatric suicidality 'black box' warning to labeling.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 523
- Publication type:
- Article
48
Pharmacologic, lifestyle recommendations may reduce hyperkalemic risk caused by ACE inhibitors/ARBs.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 523
- Publication type:
- Article
49
First-time generic approvals.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 520
- Publication type:
- Article
50
Pipeline preview.
- Published in:
- Formulary, 2004, v. 39, n. 11, p. 520
- Publication type:
- Article